“MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)”, Mediterr J Hematol Infect Dis, vol. 6, no. 1, p. e2014009, Dec. 2013, doi: 10.4084/mjhid.2014.009.